BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q1 FY2026 selling, general & admin of $6.38M rose 154.9% year over year, behind the +257.1% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 19.6% from the prior quarter. Over 3 fiscal years it compounded at +1812.4% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +217.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $6.38M+19.6% QoQ
- Last fiscal yearDec 2025
- $24.62M+217.4% YoY
- LTMMar 2026
- $28.5M+257.1% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 24.62M USD
- Year-over-year change
- +217.4%
- 4-year CAGR
- +388.2%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 24.62M | +217.4% |
| FY2024 | 2024-12-31 | 7.76M | -8.6% |
| FY2023 | 2023-12-31 | 8.49M | +240951.1% |
| FY2022 | 2022-12-31 | 3.52K | -91.9% |
| FY2021 | 2021-12-31 | 43.36K | — |
Selling, General & Admin vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +257.1% is the highest of 10, against a peer median of +39.2%.
- Over three fiscal years its annual growth of +1812.4% compares with a peer median of +11.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $239.25M USD | -26.0% | +40.7% | 116.8% | |
| LTM Mar 2026 | $171.62M USD | +82.6% | +23.3% | 122.2% | |
| LTM Aug 2026 | $78.21M USD | +57.0% | +11.6% | 11.1% | |
| LTM Sep 2026 | $76.77M USD | +79.2% | +11.4% | — | |
| LTM Jun 2026 | $65.29M USD | +5.1% | +10.3% | 62.2% | |
| LTM Mar 2026 | $62.81M USD | +42.2% | +11.5% | 27.0% | |
| LTM Sep 2026 | $42.74M USD | -6.8% | -6.1% | — | |
SEPNSepterna, Inc. | LTM Sep 2026 | $36.57M USD | +38.0% | — | 38.0% |
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | $28.5M USD | +257.1% | +1812.4% | — |
| LTM Mar 2026 | CHF 27.55M CHF | +39.2% | +54.0% | 5466.6% | |
| Peer median (excluding BBOT) | — | +39.2% | +11.5% | 62.2% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 0 | 0 | 56.29M | 73.11M | 121.2M |
| Selling, General & Admin | 43.36K | 3.52K | 8.49M | 7.76M | 24.62M |
| Operating Expenses | 43.36K | 3.52K | 64.77M | 80.86M | 145.82M |
| Depreciation & Amortization | 74.33K | 3.52K | 92K | 208K | 610K |
| EBITDA | (43.36K) | (3.52K) | (64.68M) | (80.66M) | (145.21M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (43.36K) | (3.52K) | (64.77M) | (80.86M) | (145.82M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 72K | 8.46M | 11.34M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 0 | 0 | 72K | 8.18M | 11.78M |
| Income Before Tax | (43.36K) | (3.52K) | (64.7M) | (74.28M) | (134.04M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (43.36K) | (3.52K) | (64.7M) | (74.28M) | (134.04M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.00) | 0.00 | (3.16) | 0.46 | (4.30) |
| EPS (Diluted) | (0.00) | (0.00) | (3.16) | 0.46 | (4.30) |
| Weighted Avg Shares | 20.49M | 20.49M | 20.49M | 16.64M | 31.14M |
| Weighted Avg Shares (Diluted) | 20.49M | 20.49M | 20.49M | 16.64M | 31.14M |
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.